Developing competitive and sustainable Polish generic medicines market

Croatian Medical Journal

Volumn 50, Issue 5, 2009, Pages 440-448

  Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

CLINICAL PRACTICE; COMPETITION; COST CONTROL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; POLAND; PRESCRIPTION; REIMBURSEMENT; REVIEW;

COMPUTER SIMULATION; COST CONTROL; DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; HEALTH POLICY; HUMANS; POLAND; REIMBURSEMENT MECHANISMS; REIMBURSEMENT, INCENTIVE;

EID: 72449127131     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2009.50.440     Document Type: Review

References (24)

1. Organisation for Economic Co-operation and Development (OECD). OECD health data 2009. Paris: OECD; 2009.
2. Nuijten MJ, Szende A, Kosa J, Mogyorosy Z, Kramberger B, Nemecek K, et al. Health care reform in six Central European countries. A focus on health economic requirements in the drug pricing and reimbursement processes. Eur J Health Econ. 2003;4:286-91. Medline:15609197 doi:10.1007/s10198-003-0177-2 (Pubitemid 38081992)
3. Directive 2004/27/EC of the European Parliament and of the Council of 31st March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union. L136/34-57.
4. European Generic Medicines Association. Basic notions of generics. Brussels: European Generic Medicines Association; 2008. Available from: http://198.170.119.137/gen-basics.htm. Accessed: September 23, 2009.
5. Simoens S, De Coster S. Sustaining generic medicines markets in Europe. Journal of Generic Medicines. 2006;3:257-268 doi:10.1057/ palgrave.jgm.4940128
6. European Generic Medicines Association. 2006 market review. The European generic pharmaceutical markets: price and reimbursement systems. Brussels: European Generic Medicines Association; 2007.
7. Health IMS. Midas database. London: IMS Health; 2004.
8. Habl C, Vogler S, Leopold C, Schmickl B, Froschl B. Referencepricing systems in Europe [in German]. Vienna: Austrian Health Institute; 2008.
9. Cox E, Behm A, Mager D, Miller S. Generic drug usage report. St. Louis (MO): Express Scripts; 2004.
10. Kuszewski K, Gericke C. Health systems in transition: Poland. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies; 2005.
11. Directive 1989/105/EEC of 21st December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems. Official Journal of the European Union. L 40/8-11.
12. Janiszewski R, Bondary K. Pharmaceutical pricing and reimbursement information (PPRI) profile Poland. Vienna: PPRI/ Austrian Health Institute; 2007.
13. Pharmacos. Poland -health care, pharmaceutical pricing and reimbursement. Brussels: European Commission, Enterprise and Industry DG, Directorate F -Consumer goods; 2005.
14. Willert PL. Assessment of the pharmaceutical market in Poland after accession to the European Union. Eur J Health Econ. 2007;8:347-57. Medline:17186200 doi:10.1007/s10198-006-0032-3 (Pubitemid 350043712)
15. Kazakov R. Pricing and reimbursement policies in new EU accession countries. Journal of Generic Medicines. 2007;4:249-258 doi:10.1057/palgrave. jgm.4950068
16. Collaborating WHO. Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical classification system for drugs. Available from: http://www.whocc.no. Accessed: September 23, 2009.
17. European Generic Medicines Association. How to increase patient access to generic medicines in European healthcare systems. Brussels: European Generic Medicines Association; 2009. Available from: http://www.egagenerics.com/doc/ega- increase-patientaccess-update-072009.pdf. Accessed: September 23, 2009.
18. Simoens S. Generic medicine pricing in Europe: current issues and future perspective. J Med Econ. 2008;11:171-5. Medline:19450118
19. Lopez-Casasnovas G, Puig-Junoy J. Review of the literature on reference pricing. Health Policy. 2000;54:87-123. Medline:11094265 doi:10.1016/S0168- 8510(00)00100-7 (Pubitemid 30950392)
20. Vogler S, Leopold C. Access to essential medicines in Portugal. Vienna: Austrian Health Institute; 2009.
21. National Health Fund. Medicines. Warsaw: National Health Fund; 2009. Available from: http://www.nfz.gov.pl/new. Accessed: September 23, 2009.
22. Mokrzycka A. Pharmaceutical policy -new legislation to save cost. Krakow: Jagiellonian University Medical College; 2008. Available from: http://www.hpm.org/en/Surveys/Jagiellonian-University-Poland/12/ Pharmaceutical-policy-new-legislation-to-save-cost. html;jsessionid= F4599C95BBF001E9CBB29E1FE96B72A?showDet ails=all&content-id=251&p-c: 1204=1204&a=sc&sortBy=sortCount ry&sortOrder= sortAsc&lastSortOrder=sortAsc&language=en&lastS ortBy=sortCountry. Accessed: September 24, 2009.
23. Mokrzycka A, Kowalska I. Ideas of drugs reimbursement system changes. Krakow: Jagiellonian University Medical College; 2006. Available from: http://www.hpm.org/en/Surveys/Jagiellonian-University-Poland/07/ Ideas-of-drugs-reimbursement-system-changes.html. Accessed: September 23, 2009.
24. Mokrzycka A. Ideas of drugs reimbursement system changes II. Krakow: Jagiellonian University Medical College; 2007. Available from: http://www.hpm.org/en/Surveys/Jagiellonian-University-Poland/10/ Ideas-of-drug-reimbursement-system-changes-II.html. Accessed: September 23, 2009.